The DOI matches its Crossref record; 340 of the 340 references it cites were found in a registry or an index.
Therapeutic strategies to overcome taxane resistance in cancer
Abstract
One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the emergence of multidrug resistance (MDR). Numerous studies have been published regarding potential approaches to reverse resistance to taxanes, including paclitaxel (PTX) and docetaxel, which represent one of the most important classes of anticancer drugs. Since 1984, following the FDA approval of paclitaxel for the treatment of advanced ovarian carcinoma, taxanes have been extensively used as drugs that target tumor microtubules. Taxanes, have been shown to affect an array of oncogenic signaling pathways and have potent cytotoxic efficacy. However, the clinical success of these drugs has been restricted by the emergence of cancer cell resistance, primarily caused by the overexpression of MDR efflux transporters or by microtubule alterations. In vitro and in vivo studies indicate that the mechanisms underlying the resistance to PTX and docetaxel are primarily due to alterations in α-tubulin and β-tubulin. Moreover, resistance to PTX and docetaxel results from: 1) alterations in microtubule-protein interactions, including microtubule-associated protein 4, stathmin, centriole, cilia, spindle-associated protein, and kinesins; 2) alterations in the expression and activity of multidrug efflux transporters of the ABC superfamily including P-glycoprotein (P-gp/ABCB1); 3) overexpression of anti-apoptotic proteins or inhibition of apoptotic proteins and tumor-suppressor proteins, as well as 4) modulation of signal transduction pathways associated with the activity of several cytokines, chemokines and transcription factors. In this review, we discuss the abovementioned molecular mechanisms and their role in mediating cancer chemoresistance to PTX and docetaxel. We provide a detailed analysis of both in vitro and in vivo experimental data and describe the application of these findings to therapeutic practice. The current review also discusses the efficacy of different pharmacological modulations to achieve reversal of PTX resistance. The therapeutic roles of several novel compounds, as well as herbal formulations, are also discussed. Among them, many structural derivatives had efficacy against the MDR phenotype by either suppressing MDR or increasing the cytotoxic efficacy compared to the parental drugs, or both. Natural products functioning as MDR chemosensitizers offer novel treatment strategies in patients with chemoresistant cancers by attenuating MDR and increasing chemotherapy efficacy. We broadly discuss the roles of inhibitors of P-gp and other efflux pumps, in the reversal of PTX and docetaxel resistance in cancer cells and the significance of using a nanomedicine delivery system in this context. Thus, a better understanding of the molecular mechanisms mediating the reversal of drug resistance, combined with drug efficacy and the application of target-based inhibition or specific drug delivery, could signal a new era in modern medicine that would limit the pathological consequences of MDR in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–340 of 340
Fang, C., Du, H., Jia, W. P., & Xu, Y. (2018) · Metabolites · doi:10.3390/metabo9010002 · Cited by 91
Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833
Chico, I. M., Kang, M. H., Bergan, R. C., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R. W., Choyke, P. L., Merino, M. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.832 · Cited by 90
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Targeting multidrug resistance in cancer by natural chemosensitizers
Hamed, A. R., Abdel‐Azim, N. S., Shams, K. A., & Hammouda, F. M. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0043-8 · Cited by 88
Guo, Y., He, W., Yang, S., Zhao, D., Li, Z., & Luan, Y. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.12.012 · Cited by 87
An evolutionary roadmap to the microtubule-associated protein MAP Tau
Sündermann, F., Fernández, M. P., & Morgan, R. O. (2016) · BMC Genomics · doi:10.1186/s12864-016-2590-9 · Cited by 86
Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin
Sáez-Calvo, G., Sharma, A., Balaguer, F. D. A., Barasoaín, I., Rodríguez‐Salarichs, J., Olieric, N., Muñoz-Hernández, H., Berbis, M. A., Wendeborn, S. V., Peñalva, M. A., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.016 · Cited by 86
Ruff, P., Vorobiof, D., Jordaan, J. P., Demetriou, G. S., Moodley, S. D., Nosworthy, A. L., Werner, I. D., Raats, J., & Burgess, L. J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0925-9 · Cited by 85
Nicoletti, M. I., Valoti, G., Giannakakou, P., Zhan, Z., Kim, J. H., Lucchini, V., Landoni, F., Mayo, J. G., Giavazzi, R., & Fojo, T. (2001) · PubMed · Cited by 85
Overexpression of MEKK3 Confers Resistance to Apoptosis through Activation of NFκB
Samanta, A. K., Huang, H. J., Bast, R. C., & Liao, W. S. ‐. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311659200 · Cited by 84
Kim, J., & Lee, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091854 · Cited by 84
Liu, C.-M., Kao, C., Tseng, Y., Lo, Y., & Chen, C. (2017) · Molecules · doi:10.3390/molecules22091477 · Cited by 84
Bai, Z., Gao, M., Zhang, H., Guan, Q., Xu, J., Li, Y., Qi, H., Li, Z., Zuo, D., Zhang, W., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.016 · Cited by 83
Jaffrézou, J., Dumontet, C., Derry, W. B., Durán, G. E., Chen, K. G., Tsuchiya, E., Wilson, L., Jordan, M. A., & Sikic, B. I. (1995) · PubMed · Cited by 82
Gonçalves, B. M. F., Cardoso, D., & Ferreira, M. U. (2020) · Molecules · doi:10.3390/molecules25153364 · Cited by 82
Advani, R. H., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001) · PubMed · Cited by 81
Bar-Zeev, M., Assaraf, Y. G., & Livney, Y. D. (2016) · Oncotarget · doi:10.18632/oncotarget.8019 · Cited by 81
Self-citationEssential Roles of E3 Ubiquitin Ligases in p53 Regulation
Sane, S., & Rezvani, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020442 · Cited by 81
Deng, Z., Yan, F., Jin, Q., Li, F., Wu, J., Liu, X., & Zheng, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.11.018 · Cited by 80
Cai, J., Chen, S., Zhang, W., Hu, S., Lü, J., Xing, J., & Dong, Y. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.02.012 · Cited by 80
Th, W., Chan, Y.-H., Chen, C., Kung, W.-H., Lee, Y.-S., Wang, S., Chang, T.-C., & Wang, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209498 · Cited by 79
Autophagy and Transporter-Based Multi-Drug Resistance
Kumar, P., Zhang, D., Degenhardt, K., & Chen, Z. (2012) · Cells · doi:10.3390/cells1030558 · Cited by 76
Self-citationFracasso, P. M., Goldstein, L. J., de Alwis, D. P., Rader, J. S., Arquette, M. A., Goodner, S. A., Wright, L. P., Fears, C. L., Gazak, R. J., Andre, V. A. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0452 · Cited by 76
Lee, K. M., Cao, D., Itami, A., Pour, P. M., Hruban, R. H., Maitra, A., & Ouellette, M. M. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02792.x · Cited by 75
Blade, K. L., Menick, D. R., & Cabral, F. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.13.2213 · Cited by 75
Zhang, D., & Kanakkanthara, A. (2020) · Cancers · doi:10.3390/cancers12071721 · Cited by 75
Marine Natural Products with P-Glycoprotein Inhibitor Properties
Lopéz, D., & Martínez‐Luis, S. (2014) · Marine Drugs · doi:10.3390/md12010525 · Cited by 74
The role of Tau protein in resistance to paclitaxel
Smoter, M., Bodnar, L., Duchnowska, R., Stec, R., Grala, B., & Szczylik, C. A. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1696-7 · Cited by 74
Wu, H., Chen, S., Yu, J., Li, Y., Zhang, X., Yang, L., Zhang, H., Hou, Q., Jiang, M., Brunicardi, F. C., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.059 · Cited by 74
Advanced technological tools to study multidrug resistance in cancer
Andrei, L., Kasas, S., Ochoa, I., Stanković, T., Korsnes, M. S., Václavíková, R., Assaraf, Y. G., & Pešić, M. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100658 · Cited by 74
Self-citationMatsuoka (1992) · International Journal of Oncology · doi:10.3892/ijo_00000153 · Cited by 73
Yang, Y., Lee, K., Park, H.-J., Kim, T. J., Choi, Y. S., Shih, I., & Choi, J. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs302 · Cited by 73
Karashima, M., Kimoto, K., Yamamoto, K., Kojima, T., & Ikeda, Y. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.07.006 · Cited by 73
Zhang, Y., Sriraman, S. K., Kenny, H. A., Luther, E., Torchilin, V. P., & Lengyel, E. R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0986 · Cited by 73
Duan, Z., Lamendola, D. E., Penson, R. T., Kronish, K., & Seiden, M. V. (2002) · Cytokine · doi:10.1006/cyto.2001.1008 · Cited by 72
Sarısözen, C., Vural, İ., Levchenko, T. S., Hıncal, A. A., & Torchilin, V. P. (2012) · Drug Delivery · doi:10.3109/10717544.2012.674163 · Cited by 72
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F. P., Goldspiel, B. R., Chang, R., Noone, M., Denicoff, A. M., Barnes, C. S., Gossard, M. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1173 · Cited by 72
Taxanes from Shells and Leaves of Corylus avellana
Ottaggio, L., Bestoso, F., Armirotti, A., BALBI, A., Damonte, G., Mazzei, M., Sancandi, M., & Miele, M. (2007) · Journal of Natural Products · doi:10.1021/np0704046 · Cited by 71
Tsubaki, M., Satou, T., Itoh, T., Imano, M., Komai, M., Nishinobo, M., Yamashita, M., Yanae, M., Yamazoe, Y., & Nishida, S. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.07.003 · Cited by 70
Ibrado, A. M., Kim, C. N., & Bhalla, K. N. (1998) · Leukemia · doi:10.1038/sj.leu.2401218 · Cited by 70
Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy
Shi, X., & Sun, X. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3398-2 · Cited by 70
The Elephant in the Room: The Role of Microtubules in Cancer
Cirillo, L., Gotta, M., & Meraldi, P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57127-0_5 · Cited by 69
Liao, D. K., Zhang, W., Gupta, P., Lei, Z., Wang, J., Cai, C., Vera, A. A. D., Zhang, L., Chen, Z., & Yang, D. (2019) · Molecules · doi:10.3390/molecules24234383 · Cited by 69
Self-citationXIE, Z., Cao, L., & Zhang, J. (2013) · Oncology Letters · doi:10.3892/ol.2013.1432 · Cited by 67
Souter, S., & Lee, G. S. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22287 · Cited by 67
Characterization of a Taxol‐resistant Human Small‐cell Lung Cancer Cell Line
Ohta, S., Nishio, K., Kubota, N., Ohmori, T., Funayama, Y., Ohira, T., Nakajima, H., Adachi, M., & Saijo, N. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02096.x · Cited by 67
Dawar, S., Singh, N., Kanwar, R. K., Kennedy, R. L., Veedu, R. N., Zhou, S., Krishnakumar, S., Hazra, S., Sasidharan, S., Duan, W., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.009 · Cited by 67
Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1α
Huang, L., Ao, Q., Zhang, Q., Yang, X., Xing, H., Li, F., Chen, G., Zhou, J., Wang, S., Xu, G., et al. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0675-4 · Cited by 67
The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.
Huzil, J. T., Chen, K., Kurgan, L., & Tuszyński, J. A. (2007) · PubMed Central · Cited by 64
Ferulic acid reverses ABCB1-mediated paclitaxel resistance in MDR cell lines
Muthusamy, G., Balupillai, A., Ramasamy, K., Shanmugam, M., Gunaseelan, S., Mary, B., & Prasad, N. R. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.05.023 · Cited by 64
Taxol® Biosynthesis and Production: From Forests to Fermenters
McElroy, C., & Jennewein, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-67903-7_7 · Cited by 64
International Review Of Cell and Molecular Biology
(2010) · International review of cytology · doi:10.1016/c2009-0-01759-0 · Cited by 64
Smoter, M., Bodnar, L., Grala, B., Stec, R., Zieniuk, K., Kozłowski, W., & Szczylik, C. A. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-25 · Cited by 63
Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract
Fong, W. F., Wang, C., Zhu, G., et al. (2006) · Phytomedicine · doi:10.1016/j.phymed.2006.03.004 · Cited by 60
Differentiation of human colon cancer cells changes the expression of β-tubulin isotypes and MAPs
Carles, G., Braguer, D., Dumontet, C., Bourgarel‐Rey, V., Gonçalvès, A., Sarrazin, M., Rognoni, J. B., & Briand, C. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690481 · Cited by 59
Poruchynsky, M. S., Giannakakou, P., Ward, Y., Bulinski, J. C., Telford, W. G., Robey, R. W., & Fojo, T. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00804-8 · Cited by 59
Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents
Whitaker, R. H., & Placzek, W. J. (2019) · Cells · doi:10.3390/cells8040346 · Cited by 59
El‐Zahaby, S. A., Elnaggar, Y. S. R., & Abdallah, O. Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.013 · Cited by 55
Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines
Han, E. K.-H., Gehrke, L., Tahir, S. K., Credo, R. B., Cherian, S. P., Sham, H. L., Rosenberg, S. H., & Ng, S. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00145-3 · Cited by 54
Sun, R., Liu, Z., Wang, L., Wei-dong, L., Liu, J., Ding, C., Yuan, Y., Lei, G., & Xu, C. (2015) · Tumor Biology · doi:10.1007/s13277-015-3361-y · Cited by 54
Structural insight into microtubule stabilization and kinesin inhibition by Tau family MAPs
Shigematsu, H., Imasaki, T., Doki, C., Sumi, T., Aoki, M., Uchikubo-Kamo, T., Sakamoto, A., Tokuraku, K., Shirouzu, M., & Nitta, R. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201711182 · Cited by 54
Sakurai, Y., Hada, T., Yamamoto, S., Kato, A., Mizumura, W., & Harashima, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.178 · Cited by 53
Zou, W., Sarısözen, C., & Torchilin, V. P. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1236113 · Cited by 52
Khalilzadeh, A., Wangoo, K., Morris, D. L., & Pourgholami, M. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.05.006 · Cited by 51
Qian, J. X., Shen, S., Chen, W., & Chen, N. (2018) · BioMed Research International · doi:10.1155/2018/4174232 · Cited by 51
Park, S., Seong, M. A., & Lee, H. (2016) · Oncotarget · doi:10.18632/oncotarget.6945 · Cited by 50
Huang, C., Zhang, X., Jiang, L., Zhang, L., Xiang, M., & Ren, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.05.005 · Cited by 50
Reis, M. A., Ahmed, O. B., Spengler, G., Molnar, J. A., Lage, H., & Ferreira, M. U. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.05.007 · Cited by 49
Yang, H., Mao, W., Rodriguez‐Aguayo, C., Mangala, L. S., Bartholomeusz, G. A., Iles, L. R., Jennings, N. B., Ahmed, A. A., Sood, A. K., Lopez‐Berestein, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0504 · Cited by 49
Prognostic Significance of p21 and p53 Expression in Gastric Cancer
Seo, Y., Joo, Y., Choi, S.-K., Rew, J., Park, C.-S., & Kim, S.-J. (2003) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2003.18.2.98 · Cited by 48
Ooko, E., Alsalim, T. A. Q., Saeed, B. A., Saeed, M. E. M., Kadioglu, O., Abbo, H. S., Titinchi, S. J. J., & Efferth, T. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.06.002 · Cited by 48
Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account
Collado‐Borrell, R., Escudero‐Vilaplana, V., Romero-Jiménez, R. M., Peinado, I. I., Alonso, A. H., & Sanjurjo‐Sáez, M. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2190-8 · Cited by 48
Jin, Q., Xia, M., Liu, W., Li, L., Yang, J., Mei, Y., Meng, Q., & Xie, Y. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.002 · Cited by 48
Savry, A., Carre, M., Bergès, R., Rovini, A. M. F., Pobel, I., Chacon, C., Braguer, D., & Bourgarel‐Rey, V. (2013) · Neoplasia · doi:10.1593/neo.121074 · Cited by 46
Zhong, P., Chen, X., Guo, R., Chen, X., Chen, Z., Cui, W., Li, Y., Wang, W. “., Zhou, Y., & Qin, L. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01148 · Cited by 46
Self-citationDeceivingly dynamic: Learning-dependent changes in stathmin and microtubules
Uchida, S., & Shumyatsky, G. P. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.07.011 · Cited by 45
Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells
Huang, K., Yang, J., Ng, M. C., Ng, S., Welch, W. R., Muto, M. G., Berkowitz, R. S., & Ng, S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.007 · Cited by 45
p53 acetylation enhances Taxol-induced apoptosis in human cancer cells
Kim, J. H., Yoon, E.-K., Chung, H. J., Park, S.-Y., Hong, K., Lee, C. H., Lee, Y.-S., Choi, K., Yang, Y. D., Kim, K., et al. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0772-8 · Cited by 44
Malingré, M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., van Tellingen, O., Duchin, K., Huinink, W. W. T. B., Swart, M., Lieverst, J. A., & Schellens, J. H. M. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000226 · Cited by 44
Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators
Pajeva, I. K., & Wiese, M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9118-z · Cited by 44
Zhang, H., Patel, A. S., Wang, Y.-J., Zhang, Y.-K., Kathawala, R. J., Qiu, L., Patel, B. A., Huang, L.-H., Shukla, S., Yang, D., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0511 · Cited by 42
Self-citationNithianantham, S., Cook, B., Beans, M., Guo, F., Chang, F., & Al‐Bassam, J. (2018) · eLife · doi:10.7554/elife.38922 · Cited by 42
Estève, M., Carré, M., Bourgarel‐Rey, V., Kruczynski, A., Raspaglio, G., Ferlini, C., & Braguer, D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0277 · Cited by 41
Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer
Bae, T., Weon, K.-Y., Lee, J., Eum, K., Kim, S., & Choi, J. W. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv140 · Cited by 41
Werner, H. M. J., Trovik, J., Halle, M. K., Wik, E., Akslen, L. A., Birkeland, E., Bredholt, T., Tangen, I. L., Krakstad, C., & Salvesen, H. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090141 · Cited by 40
Mutation of the class I β-tubulin gene does not predict response to paclitaxel for breast cancer
Maeno, K., Ito, K., Hama, Y., Shingū, K., Kimura, M., Sano, M., Nakagomi, H., Tsuchiya, S., & Fujimori, M. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00279-9 · Cited by 40
田淵, 陽. (2009) · Institutional Repositories DataBase (IRDB) · Cited by 40
Zhou, M., Zhang, Q., Zhao, J., Liao, M., Wen, S., & Yang, M. (2017) · Oncology Reports · doi:10.3892/or.2017.5830 · Cited by 40
Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types
Ben‐Hamo, R., Zilberberg, A., Cohen, H., Bahar‐Shany, K., Wachtel, C., Korach, J., Aviel‐Ronen, S., Barshack, I., Barash, D., Levanon, K., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0084-3 · Cited by 40
Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids
Zeino, M., Paulsen, M. S., Zehl, M., Urban, E., Kopp, B., & Efferth, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.009 · Cited by 38
Sobue, S., Mizutani, N., Aoyama, Y., Kawamoto, Y., Suzuki, M., Nozawa, Y., Ichihara, M., & Murate, T. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.128 · Cited by 38
Nakamura, K., Sawada, K., Miyamoto, M., Kinose, Y., Yoshimura, A., Ishida, K., Kobayashi, M., Shimizu, A., Nakatsuka, E., Hashimoto, K., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26586 · Cited by 38
Paclitaxel resistance in cells with reduced β-tubulin
Wang, Y., & Cabral, F. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.12.003 · Cited by 37
Shi, X., Dou, Y., Zhou, K., Huo, J., Yang, T., Qin, T., Liu, W., Wang, S., Yang, D., Chang, L., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.043 · Cited by 37
Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances
Matesanz, R., Trigili, C., Rodríguez‐Salarichs, J., Zanardi, I., Pera, B., Nogales, A., Fang, W., Jiménez‐Barbero, J., Canales, Á., Barasoaı́n, I., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.048 · Cited by 36
Elnaggar, Y. S. R., Elsheikh, M. A., & Abdallah, O. Y. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0220 · Cited by 36
Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1
Dong, X. L., Xu, P., Miao, C., Fu, Z.-Y., Li, Q. P., Tang, P., & Wang, T. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.11.016 · Cited by 34
Biaoxue, R., Liu, H., Wenlong, G., & Shuanying, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12982 · Cited by 34
Umsumarng, S., Pitchakarn, P., Yodkeeree, S., Punfa, W., Mapoung, S., Ramli, R. A., Pyne, S. G., & Limtrakul, P. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.08.004 · Cited by 32
Manzoor, S., Bilal, A., Khan, S., Ullah, R., Iftikhar, S., Emwas, A.-H. M., Alazmi, M., Gao, X., Jawaid, A., Saleem, R. S. Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21642-0 · Cited by 32
Risinger, A. L., & Du, L. (2019) · Natural Product Reports · doi:10.1039/c9np00053d · Cited by 32
Wang, Y., Chen, Q., Jin, S., Deng, W., Li, S., Tong, Q., & Chen, Y. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.683042 · Cited by 31
Tagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Bello, M. G. D., Boccardo, S., Grossi, F., & Alama, A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1627326 · Cited by 31
Gao, L., Zhao, P., Yang, L., Yang, D., Hu, P., Li, L., Cheng, Y., & Yao, H.-C. (2020) · Biochemistry and Cell Biology · doi:10.1139/bcb-2019-0377 · Cited by 31
Liu, B. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i6.855 · Cited by 30
Cohen-Solal, K., Kaufman, H. L., & Lasfar, A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12666 · Cited by 30
Wang, W., Zhang, H., Wang, X., Patterson, J., Winter, P., Graham, K., Ghosh, S., Lee, J. C., Katsetos, C. D., Mackey, J. R., et al. (2016) · PROTOPLASMA · doi:10.1007/s00709-016-1060-1 · Cited by 28
Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy
Gupta, D., Kumar, M., Tyagi, P., Kapoor, S., Tyagi, A. K., Barman, T. K., Kharbanda, S. M., Kufe, D. W., & Singh, H. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.03.010 · Cited by 28
Youssef, S. F., Elnaggar, Y. S. R., & Abdallah, O. Y. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0238 · Cited by 28
Yang, Y., Hsu, Y.-T., Wu, C.-C., Chen, H.-T., & Chang, M.-S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.166 · Cited by 27
Koo, D., Lee, H. J., Ahn, J. H., Yoon, D. H., Kim, S., Gong, G., Son, B. H., Ahn, S. H., & Jung, K. H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3258-9 · Cited by 26
Yang, X., Shen, J. K., Gao, Y., Feng, Y., Guan, Y., Zhang, Z., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2015) · International Journal of Cancer · doi:10.1002/ijc.29574 · Cited by 25
Microtubule dynamics: moving toward a multi-scale approach
Hemmat, M., Castle, B. T., & Odde, D. J. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.12.013 · Cited by 25
Selective Drug Resistant Human Osteosarcoma Cell Lines
Burns, B. S., Edin, M. L., Lester, G. E., Tuttle, H. G., Wall, M. E., Wani, M. C., & Bos, G. D. (2001) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200102000-00030 · Cited by 24
Microinjection of intact MAP-4 and fragments induces changes of the cytoskeleton in PtK2 cells
Yoshida, T., Imanaka‐Yoshida, K., Murofushi, H., Tanaka, J., Ito, H., & Inagaki, M. (1996) · Cell Motility and the Cytoskeleton · doi:10.1002/(sici)1097-0169(1996)33:4<252::aid-cm2>3.0.co;2-b · Cited by 24
Podolski-Renić, A., Banković, J., Dinić, J., Ríos‐Luci, C., Fernandes, M. X., Ortega, N., Kovačević‐Grujičić, N., Martı́n, V. S., Padrón, J. M., & Pešić, M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.011 · Cited by 24
Elsheikh, M. A., Elnaggar, Y. S. R., Otify, D. Y., & Abdallah, O. Y. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2307-z · Cited by 23
Contemporary Formulations for Drug Delivery of Anticancer Bioactive Compounds
Ackova, D. G., Smilkov, K., & Bosnakovski, D. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666190111104834 · Cited by 23
LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP
Lai, H., Wang, R., Li, S., Shi, Q., Cai, Z., Li, Y., & Liu, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9581-8 · Cited by 23
Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years
Tao, H., Zuo, L., Xu, H., Li, C., Qiao, G., Guo, M., & Lin, X. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200131120618 · Cited by 23
Khonkarn, R., Daowtak, K., & Okonogi, S. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01657-5 · Cited by 22
Ling, Y. H., Zou, Y., & Pérez-Soler, R. (2000) · PubMed · Cited by 21
Liu, Y., Li, G., Liu, C., Tang, Y., & Zhang, S. (2017) · Journal of Cancer · doi:10.7150/jca.16720 · Cited by 21
Rai, A., Kapoor, S., Naaz, A., Santra, M. K., & Panda, D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.018 · Cited by 21
Yoshizawa, Y., Ogawara, K., Kimura, T., & Higaki, K. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.06.009 · Cited by 20
Li, K., Li, M., Luo, Z. Y., Mao, Y., Yu, Y., He, Y., Zhou, J., Fei, Y., Pei, Y., & Cai, K. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.010 · Cited by 20
Bai, Z., Liu, X., Guan, Q., Ding, N., Wei, Q., Tong, B., Zhao, M., Zhang, W., & Ma, L. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108886 · Cited by 19
Prunotto, A., Stevenson, B. J., Berthonneche, C., Schüpfer, F., Beckmann, J. S., Maurer, F., & Bergmann, S. (2016) · BMC Genomics · doi:10.1186/s12864-016-3059-6 · Cited by 17
Paclitaxel suppresses Tau-mediated microtubule bundling in a concentration-dependent manner
Choi, M. C., Chung, P. J., Song, C., Miller, H. P., Kiris, E., Li, Y., Wilson, L., Feinstein, S. C., & Safinya, C. R. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.09.011 · Cited by 17
Jin Wei, L. U., Yingchun, W., Zhujun, S., Wu, Y., Wu, D., Yu, H., Xi, Y., Wanzhou, Z., Buluan, Z., & Jinhua, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108992 · Cited by 16
Natural Product as Substrates of ABC Transporters: A Review
Chen, X.-Y. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/22123970mte01mzcvy · Cited by 16
Hyuga, S., Shiraishi, M., Hori, A., Hyuga, M., & Hanawa, T. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00371 · Cited by 14
The role of ABC transporters in anticancer drug transport
Karvar, S. (2014) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1407-3 · Cited by 13
White, D., Honoré, S., & Hubert, F. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.06.014 · Cited by 13
Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers.
Ross, H. J., Canada, A. L., & Slater, L. M. (1997) · PubMed · Cited by 12
Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms
Hasanpourghadi, M., Pandurangan, A. K., & Mustafa, M. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-53082-6_2 · Cited by 12
Current Strategies in Cancer Gene Therapy
Walther, W. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2 · Cited by 10
Ding, J., Li, M., Deng, L., & Li, T. (2018) · BioMed Research International · doi:10.1155/2018/8372085 · Cited by 10
Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents
Anaya-Ruı́z, M., Bandala, C., Landeta‐Cortés, G., Martínez‐Morales, P., Zumaquero-Ríos, J. L., Pérez, J. S., & Pérez-Santos, M. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666181031154146 · Cited by 6
Fan, Y., Hou, X., & Fang, H. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200916124641 · Cited by 5
Research works printed but not linked: 43
- Bevis, 2014, Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study, J. Reprod. Med., 59, 113
- Cai, 2014, Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway, Phytomedicine, 21, 1725, 10.1016/j.phymed.2014.08.007 · doi:10.1016/j.phymed.2014.08.007
- Cao, 2013, Characterization of flavonoids from Dryopteris erythrosora and evaluation of their antioxidant, anticancer and acetylcholinesterase inhibition activities, Food Chem. Toxicol., 51, 242, 10.1016/j.fct.2012.09.039 · doi:10.1016/j.fct.2012.09.039
- Dong, 2017, Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells, J. Zhejiang Univ. Sci. B, 18, 76, 10.1631/jzus.B1600357 · doi:10.1631/jzus.b1600357
- Elnaggar, 2017, Self-emulsifying preconcentrates of daidzein–phospholipid complex: design, in vitro and in vivo appraisal, Nanomedicine, 12, 893, 10.2217/nnm-2016-0387 · doi:10.2217/nnm-2016-0387
- Guntur, 2010, Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro, Anticancer Res., 30, 3557
- Guo, 2017, Research progress in reversal of tumor multi-drug resistance via natural products, Anticancer Agents Med. Chem., 17, 1466, 10.2174/1871520617666171016105704 · doi:10.2174/1871520617666171016105704
- Haider, 2019, Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018), Expert Opin. Ther. Pat., 29, 623, 10.1080/13543776.2019.1648433 · doi:10.1080/13543776.2019.1648433
- Han, 2013, Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2, Cancer Biother. Radiopharm., 28, 398
- He, 2014, The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin, Med. Oncol., 31, 950, 10.1007/s12032-014-0950-3 · doi:10.1007/s12032-014-0950-3
- Hsieh, 2014, Psoralen reverses docetaxel-induced multidrug resistance in A549/D16 human lung cancer cells lines, Phytomedicine, 21, 970, 10.1016/j.phymed.2014.03.008 · DOI
- Huo, 2021, A combined bioinformatic and nanoparticle-based study reveal the role of ABCG2 in the resistance of breast Cancer, Recent Pat. Anticancer Drug Discov.
- Kars, 2013, Exploring a natural MDR reversal agent: potential of medicinal food supplement Nerium oleander leaf distillate, Asian Pac. J. Trop. Biomed., 3, 644, 10.1016/S2221-1691(13)60130-6 · doi:10.1016/s2221-1691(13)60130-6
- Kars, 2013, Paclitaxel resistance in MCF-7/Pac cell line is reversed successfully by Saikosaponin A and saikosaponin D, Int. J. Hematol. Oncol., 24, 227, 10.4999/uhod.13009 · doi:10.4999/uhod.13009
- Kawami, 2010, Effect of Thai plant extracts on P-glycoprotein function and viability in paclitaxel-resistant HepG2 cells, Drug Metab. Pharmacokinet., 25, 155, 10.2133/dmpk.25.155 · doi:10.2133/dmpk.25.155
- Kovalev, 2013, Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer, Exp. Oncol., 35, 287
- Lee, 2018, 10-Phenyltriazoyl artemisinin is a novel P-glycoprotein inhibitor that suppresses the overexpression and function of P-glycoprotein, Curr. Pharm. Des., 24, 5590, 10.2174/1381612825666190222155700 · doi:10.2174/1381612825666190222155700
- Li, 2018, Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway, BMC Cancer, 18, 1, 10.1186/s12885-018-5130-y · doi:10.1186/s12885-018-5130-y
- Li, 2020, Activity and mechanism of flavokawain A in inhibiting permeability glycoprotein expression in paclitaxel resistance of lung cancer, Oncol. Lett., 19, 379
- Limtrakul, 2007, Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells, Phytomedicine, 14, 381, 10.1016/j.phymed.2007.03.006 · doi:10.1016/j.phymed.2007.03.006
- Liu, 2014, Compound injection of shenqi as a reversal drug on docetaxel resistant human lung adenocarcinoma cell A549/DTX, Vol. 926, 1054
- Liu, 2020, Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action, Aging (Albany NY), 12, 3713, 10.18632/aging.102842 · doi:10.18632/aging.102842
- Malesinski, 2015, Stathmin potentiates vinflunine and inhibits Paclitaxel activity, PLoS One, 10, e0128704, 10.1371/journal.pone.0128704 · doi:10.1371/journal.pone.0128704
- Markman, 2000, Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer, Clin. Cancer Res., 6, 4201
- Matthews, 2006, MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia, Leuk. Lymphoma, 47, 2308, 10.1080/10428190600881421 · doi:10.1080/10428190600881421
- Peña-Solórzano, 2018, Tariquidar-related chalcones and ketones as ABCG2 modulators, ACS Med. Chem. Lett., 9, 854, 10.1021/acsmedchemlett.8b00289 · doi:10.1021/acsmedchemlett.8b00289
- Reinecke, 2000, Multidrug resistance phenotype and paclitaxel (taxol) sensitivity in human renal carcinoma cell lines of different histologic types, Cancer Invest., 18, 614, 10.3109/07357900009032828 · doi:10.3109/07357900009032828
- Ren, 2016, Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer, Biochim. Biophys. Acta, 1866, 266
- Ren, 2017, Cardiac glycoside constituents of Streblus asper with potential antineoplastic activity, J. Nat. Prod., 80, 648, 10.1021/acs.jnatprod.6b00924 · doi:10.1021/acs.jnatprod.6b00924
- Revalde, 2015, Heterocycliccyclohexanone monocarbonyl analogs of curcumin can inhibit the activity ofATP-binding cassette transporters in cancer multidrug resistance, Biochem. Pharmacol., 93, 305, 10.1016/j.bcp.2014.12.012 · doi:10.1016/j.bcp.2014.12.012
- Russo, 2019, Toward a personalized use of paclitaxel, Recent Pat. Anticancer Drug Discov., 14, 296, 10.2174/157489281404191220161014 · doi:10.2174/157489281404191220161014
- Schroeder, 2019, Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer, BMC Cancer, 19, 193, 10.1186/s12885-019-5390-1 · doi:10.1186/s12885-019-5390-1
- Shehata, 2016, Self-emulsifying phospholipid pre-concentrates (SEPPs) for improved oral delivery of the anti-cancer genistein: development, appraisal and ex-vivo intestinal permeation, Int. J. Pharm., 511, 745, 10.1016/j.ijpharm.2016.07.078 · doi:10.1016/j.ijpharm.2016.07.078
- Sootichote, 2018, Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8, BMC Cancer, 18, 231, 10.1186/s12885-018-4155-6 · doi:10.1186/s12885-018-4155-6
- Tan, 2012, Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer, Breast Cancer Res. Treat., 131, 849, 10.1007/s10549-011-1500-8 · doi:10.1007/s10549-011-1500-8
- Twentyman, 1997, Transport proteins in drug resistance: biology and approaches to circumvention, J. Intern. Med. Suppl., 740, 133, 10.1111/joim.1997.242.s740.133 · doi:10.1111/joim.1997.242.s740.133
- Vogelstein, 2010, p53: the most frequently altered gene in human cancers, Nat. Educ., 3, 6
- Watanabe, 2013, BCL 2 and BCL xL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells, Exp. Dermatol., 22, 518, 10.1111/exd.12185 · doi:10.1111/exd.12185
- Wu, 2014, A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells, Cell Oncol. (Dordr)., 37, 53, 10.1007/s13402-013-0163-3 · doi:10.1007/s13402-013-0163-3
- Yang, 2011, Reversal of multidrug resistance in human breast cancer cells by Curcuma wenyujin and Chrysanthemum indicum, Phytomedicine, 18, 710, 10.1016/j.phymed.2010.11.017 · doi:10.1016/j.phymed.2010.11.017
- Yu, 2018, Soluble resistance-related calcium-binding protein in cancers, Clin. Chim. Acta, 486, 369, 10.1016/j.cca.2018.08.034 · doi:10.1016/j.cca.2018.08.034
- Zhao, 2012, YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance, Cancer Lett., 314, 54, 10.1016/j.canlet.2011.09.013 · doi:10.1016/j.canlet.2011.09.013
- Zhou, 2009, Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance, Biochem. Pharmacol., 77, 993, 10.1016/j.bcp.2008.12.005 · doi:10.1016/j.bcp.2008.12.005
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Self-citationAnticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Self-citationPFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer
Hong, J., Du, K., Zhang, W., Jiang, Y., Yu, H., Pan, T., Wu, T., Zhao, L., Du, W., Zheng, S.-S., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c08669 · Cited by 16
Metadata
- Authors
- Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 55
- Pages
- 100754
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3133748827
- Cited by
- 253
- References
- 340
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Presidency University
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.